United InnoMed Secures Over RMB 100 Million in Series A Funding to Advance Breakthrough Heart Failure Management Technologies

VCBeat learned第一时间 that United InnoMed^®(United InnoMed^®) Completed a new round of financing exceeding 100 million yuan. This round of financing was led byLapamCapitalAndDalton VentureCo-led by Yunion Healthcare Ventures and Hunan Tianrui Harvest Equity Investment, with existing shareholders participating.Lilly Asia VenturesContinued support, Dianshi Capital serves as the exclusive financial advisor. This round of financing will mainly be used for the research and development and registration clinical trials of several core products under development by the company.

United InnoMed^®(United InnoMed^®) was founded in 2020, focusing on the development of innovative Class III active implantable products, and is committed to providing cost-effective "closed-loop" heart failure management solutions for heart failure patients worldwide. At this stage, the products under research cover the management of both acute and chronic heart failure patients, mainly including: ①For chronic heart failure patients, a long-term implantable product that integrates "treatment + diagnosis"; ②For hospitalized patients with acute heart failure, short-term Electrical Circulatory Support (ECS) used as an electrical stimulation circulatory assistance product. Both products have completed dozens of animal experiments and are initiating registration clinical trials in China.

All of the company's products under development are independently researched and globally pioneering, with over a hundred domestic and international invention patents applied for cumulatively. Since its establishment, the company has been committed to building a truly comprehensive closed-loop management ecosystem for both acute and chronic heart failure that integrates "treatment + assessment + chronic disease management." It has also established multiple technologically advanced and highly collaborative platforms. Through extensive research and validation, the company aims to promote its products to serve heart failure patients in China and around the world.

Dr. Wang Li, Founder and CEO of the company,Dr. Wang Li is a national-level overseas high-tier talent who has deeply engaged in the field of Class III active implantable heart failure and CRM (Cardiac Rhythm Management) for over 30 years. He previously served as the Chief Scientist at Medtronic headquarters, "Technology Fellow," and BU Head of the pacemaker business in Greater China. He led or was a key contributor to the development and global launch of numerous innovative pacemaker/heart failure products, five of which were groundbreaking, world-first products and therapies in the industry at that time. Dr. Wang also served as the first CEO of Shanghai-based United InnoMed, a leading medical device company in China, where he led the team to achieve the market launch of the first "internationally qualified, made in China" pacemaker, which was included in the Ministry of Science and Technology’s 2018 "Innovative Medical Device Product Catalog." Dr. Wang Li assisted associations and top experts in innovatively proposing and promoting the concept of 1.5-level prevention globally, significantly accelerating the adoption of new ICD therapies in China, and this concept was incorporated into the 2021 Chinese ICD Expert Consensus.

Dr. Wang Li is a Fellow of the Heart Rhythm Society (Fellow of HRS) in the United States. She was awarded the "Outstanding Contribution Award" by the Cardiac Electrophysiology and Pacing Branch of the Chinese Medical Association in 2014. She has successively been elected as the Vice Chairman of the National Active Implantable Devices Subcommittee, the Chairman of the Medical Device Professional Committee of the Biomedical Industry Association in Pudong New Area, Shanghai, a Director of the Shanghai Jiaotong University Medical Device Industry Alumni Association, a Review Expert for the "Intelligent Creation Cup" Frontier Technology Challenge, and an Expert of the Yangtze River Delta G60 Sci-Tech Innovation Corridor Advisory Committee, among other positions.

The company has gathered a group of outstanding talents with rich experience, innovative thinking, and international perspectives in the field of Class III implantable medical devices (including sensors) development, covering backgrounds in quality, R&D, medicine, clinical, manufacturing, registration, and management. Among them, over 80% are R&D personnel, more than 40% hold master's or doctoral degrees, and the core team’s average experience in management and R&D exceeds 15 years.

United InnoMed^®(United InnoMed^®) With the mission of "Ultimate Life, Ultimate Living," it is committed to becoming a pioneer in novel device therapies in the field of heart failure worldwide, providing high-quality heart failure management products and services to patients in China and even around the world, improving quality of life and extending lifespan.

Mr. Yu Zhihua, Founding Partner of LapamCapital, the lead investor of this roundHeart failure is the severe and end-stage of various heart diseases, with a high incidence rate and a large patient base. With the aging population and the high prevalence of related chronic diseases, the number of heart failure patients will continue to grow, making it one of the most significant cardiovascular diseases today. Currently, clinical diagnosis and treatment methods for heart failure are relatively limited, leaving a relative clinical gap, while market demand is substantial. The founding team of United InnoMed has over 30 years of experience in innovative product research and development, clinical work, and market promotion in the field of heart failure. They provide a "closed-loop" heart failure management solution for acute/chronic heart failure patients, with a relatively complete product line layout. Their products feature unique innovation and extremely high technical barriers. LapamCapital is delighted to collaborate with United InnoMed and looks forward to the company developing effective and low-cost products as soon as possible to benefit the vast number of heart failure patients.

Mr. Huang Ning, Founding Partner of Dalton Venture, the lead investor of this roundAs the aging population trend accelerates, heart failure, being the endpoint of cardiovascular diseases, affects a large number of patients and imposes a significant social burden. The mortality and readmission rates for heart failure patients remain high, with expensive treatment costs. There is a substantial demand in the market for long-term and effective management concepts and methods for heart failure patients. However, there are few device-based therapies for heart failure, creating an urgent need for innovative technologies to promote cost-effective treatments and accelerate their adoption. We are optimistic about the United InnoMed team. The founder has over 30 years of experience in active implants and the field of heart failure and possesses extensive expertise in product development and commercialization. Based on a profound understanding of the mechanisms of heart failure, the company has developed a globally innovative product pipeline. It is the first in the world to deploy products that combine both therapeutic and diagnostic functions for chronic heart failure while innovatively designing devices for acute heart failure treatment, filling a clinical gap in this area. This truly realizes a "closed-loop" model for heart failure management and provides a complete solution.

Existing shareholder Lilly Asia Ventures (LAV)Representation: The number of heart failure patients in China exceeds 12 million, with an annual increase of about 3 million. Globally, the number of heart failure patients reaches over 60 million, making heart failure a significant global public health issue. In the irreversible progression of heart failure, especially in the treatment of moderate to severe acute and chronic heart failure, medical devices are considered the most promising breakthrough in heart failure treatment. Focusing on the significant unmet clinical needs of heart failure patients worldwide, United InnoMed is committed to developing intelligent and innovative Class III implantable medical devices that integrate "treatment and diagnosis," providing the next generation of therapeutic options for heart failure patients to improve their quality of life and reduce mortality rates. We are very optimistic about this. Lilly Asia Ventures (LAV) has continuously supported United InnoMed through multiple rounds of funding and is delighted to collaborate with many new and existing investors to further empower the company and offer more clinically valuable innovative solutions to patients and doctors.